3 Under-the-Radar Small-Caps Riding the AI Insurance Boom

Everyone is watching the AI giants fight over cloud market share. Nobody is watching what happens downstream. AON's CFO Edmund Reese let something slip on a recent Bloomberg call that should have lit up every small-cap radar on the planet: traditional insurance capacity is completely insufficient for AI data center builds valued at $20 to $50 billion per site, and AON is estimating a $10 billion premium opportunity just to cover the construction phase. That's before you get to operations, cyber liability, or physical damage from, say, a drone strike near the Suez Canal.

So while the macro crowd screams about Iran and the Fed, here are three names flying so far under the radar they're basically in a submarine.

Pick 1: Kingsway Financial Services ($KFS, NYSE) is a Chicago-based specialty insurance holding company with a market cap under $500 million that almost nobody outside of niche insurance circles has heard of. The company has been quietly restructuring its warranty and niche insurance lines, pivoting toward higher-margin specialty risk. It is exactly the kind of small insurer that gets acquired or re-rated when the specialty insurance market heats up. The catalyst here is a broader industry repricing cycle driven by AI infrastructure risk, which is creating a tide that lifts boats nobody even knew were in the water.

Pick 2: Palomar Holdings ($PLMR, NASDAQ) is a specialty insurer focused on hard-to-place risks including earthquake, hurricane, and flood coverage. Market cap sits around $2 billion, squarely mid-cap but still ignored by most retail investors. With geopolitical instability driving demand for catastrophe coverage and the AI buildout creating entirely new categories of infrastructure risk, Palomar's specialty underwriting model is a direct beneficiary. The bull case is a re-rating as the market wakes up to specialty insurance demand. The bear case is a major catastrophe event that overwhelms their reinsurance stack.

Pick 3: Kali-Extrakt... actually, let's talk $HROW (Harrow, NASDAQ), a niche pharmaceutical company with a market cap under $1 billion that focuses on ophthalmology compounding. It sounds totally unrelated until you realize: with AI workforces aging and screen time exploding, the eye health space is quietly printing money. Harrow posted strong revenue growth in its last quarter and is expanding its proprietary drug pipeline. The specific catalyst is FDA clarity on its lead compounded formulations, which could move this stock significantly in either direction before year end.

None of these three names will show up in the average investor's feed today. That's kind of the whole point. By the time they do, the easy money is usually already gone.